Clinical Resources

MELD-XI Calculator

Model for End-Stage Liver Disease Excluding INR — For Anticoagulated Patients

MELD-XI removes INR from the standard MELD equation, making it suitable for patients on warfarin, DOACs, or other anticoagulants where INR is therapeutically elevated and does not reflect hepatic synthetic function. Widely used in advanced heart failure, LVAD candidacy evaluation, and transplant listing.

Values <1.0 are set to 1.0 for calculation
Values <1.0 set to 1.0; capped at 4.0

Optional — Compare with Standard MELD & MELD-Na

Values <1.0 set to 1.0
Bounded 125–137 for MELD-Na calculation

When to Use MELD-XI vs Standard MELD

  • Use MELD-XI when: The patient is on warfarin, a DOAC, or any anticoagulant that alters INR. INR in these patients reflects anticoagulation intensity, not hepatic synthetic function, making standard MELD unreliable.
  • LVAD Evaluation: MELD-XI is the preferred metric for assessing hepato-renal dysfunction in LVAD candidates and post-implant surveillance. Elevated MELD-XI (>17) pre-LVAD is associated with significantly higher post-operative mortality.
  • Transplant Listing: Useful as a supplemental risk score in heart transplant evaluation to quantify end-organ dysfunction burden independent of anticoagulation status.
  • Use Standard MELD when: The patient is not on anticoagulation and INR reflects true hepatic synthetic function (e.g., liver transplant listing, cirrhosis evaluation).

Formula

MELD-XI = 5.11 × ln(Bilirubin) + 11.76 × ln(Creatinine) + 9.44

Minimum values: Creatinine and Bilirubin are set to 1.0 if <1.0. Maximum Creatinine capped at 4.0.

Limitations

  • MELD-XI was derived and validated primarily in heart failure and LVAD populations — may not perform identically in primary liver disease.
  • Does not account for other markers of hepatic dysfunction (albumin, platelets, portal hypertension).
  • Creatinine may be influenced by muscle mass, fluid status, and diuretic therapy — consider cystatin C-based alternatives when available.
  • Not validated for organ allocation priority (UNOS uses standard MELD/MELD-Na for liver transplant listing).

References

  1. Abe S, Yoshihisa A, Takiguchi M, et al. Liver dysfunction assessed by Model for End-Stage Liver Disease Excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failure. PLoS One. 2014;9(6):e100618. doi:10.1371/journal.pone.0100618
  2. Grimm JC, Lui C, Engelman DT, et al. A MELD-XI score-based risk model to predict perioperative mortality in patients undergoing left ventricular assist device implantation. J Card Surg. 2015;30(12):880-885. doi:10.1111/jocs.12638
  3. Deo SV, Al-Kindi SG, Altarabsheh SE, et al. Model for End-Stage Liver Disease Excluding International Normalized Ratio (MELD-XI) score predicts heart transplant outcomes: Evidence from the registry of the United Network for Organ Sharing. J Heart Lung Transplant. 2016;35(2):222-227. doi:10.1016/j.healun.2015.10.008